Abstract: Disclosed are compositions, kits, and methods for treating cancer in a subject in need thereof. The compositions, kits, and methods may be used to treat a tumor in a subject in situ. The compositions, kits, and methods comprise or utilize cytotoxic particles, immune checkpoint inhibitors, and/or T-cell stimulatory agents.
Type:
Grant
Filed:
May 16, 2016
Date of Patent:
June 11, 2019
Assignee:
University of Iowa Foundation
Inventors:
Aliasger K. Salem, Amani Makkouk, Vijaya B. Joshi, George Weiner
Abstract: The present invention is directed to methods of inhibiting or preventing photophobia in subjects in need thereof using anti-CGRP antibodies or antibody fragments that inhibit photophobia, especially CGRP-associated photophobia. These antibodies and fragments are useful in treating different disorders associated with photophobia such as migraine, cluster headaches and the like. The present invention also provides assays using transgenic Nestin/Ramp1 rodents, utilizing a CGRP model light aversive behavior model for identifying therapeutically effective anti-CGRP antibodies and fragments thereof having binding specificity for CGRP which inhibit or prevent photophobia in subjects in need thereof. The present invention is specifically directed to methods for identifying therapeutically effective antibodies and fragments thereof having binding specificity for CGRP that may be used to treat CGRP associated disorders such as migraine.
Type:
Grant
Filed:
June 13, 2017
Date of Patent:
April 23, 2019
Assignees:
ALDERBIO HOLDINGS LLC, THE UNIVERSITY OF IOWA FOUNDATION
Inventors:
Andrew F. Russo, Eric A. Kaiser, Ana Recober, Adisa Kuburas, Ann C. Raddant, Brian R. Kovacevich, John Latham, Jeffrey T. L. Smith, Leon F. Garcia-Martinez
Abstract: Nucleic acid sequences containing unmethylated CpG dinucleotides that modulate an immune response including stimulating a Th1 pattern of immune activation, cytokine production, NK lytic activity, and B cell proliferation are disclosed. The sequences are also useful as a synthetic adjuvant.
Type:
Grant
Filed:
November 21, 2003
Date of Patent:
August 30, 2011
Assignees:
University of Iowa Foundation, The United States of America as represented by the Department of Health and Human Services, Coley Pharmaceutical Group, Inc.
Inventors:
Arthur M. Krieg, Alfred D. Steinberg, Dennis Klinman
Abstract: Aziridines may be subjected to a cyclooligomerization reaction to produce polyazacycloalkane compounds useful for example in the preparation of chelating agents for use in diagnostic imaging contrast agents. N-benzyl-aziridine in particular is useful as it can be cyclotetramerized and debenzylated to yield cyclen, a key intermediate in chelating agent preparation. The invention provides a particularly attractive route to production of N-benzyl and other N-arylmethyl aziridines of formula (I) where each R.sub.1 is independently hydrogen or a group AR and Ar is an optionally substituted phenyl group. The process comprises reacting a purified N-arylmethylethanolaminesulphonate ester with a base. N-arylmethyl-ethanolamine sulphonate ester of the formula R'NHCH.sub.2 CH.sub.2 OSO.sub.3 H, wherein the N-arylmethyl group R' is an N-(bisarylmethyl) or N-(triarylmethyl) group, as intermediates. In a further aspect, the invention provides compounds of formula (II) ##STR1## where Ar and R.sub.
Type:
Grant
Filed:
December 2, 1997
Date of Patent:
April 11, 2000
Assignees:
Nycomed Salutar, Inc., University of Iowa Foundation
Inventors:
Janis Vasilevskis, John Varadarajan, Martha Garrity, Jere Douglas Fellmann, Louis Messerle, Gandara Amarasinghe